These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9313316)

  • 1. Dendritic cells for the immunotherapy of renal cell carcinoma.
    Thurnher M; Klocker H; Papesh C; Ramoner R; Radmayr C; Hobisch A; Gastl G; Romani N; Ebner S; Böck G; Bartsch G
    Urol Int; 1997; 59(1):1-5. PubMed ID: 9313316
    [No Abstract]   [Full Text] [Related]  

  • 2. Dendritic cell-based immunotherapy of renal cell carcinoma.
    Gitlitz BJ; Figlin RA; Pantuck AJ; Belldegrun AS
    Curr Urol Rep; 2001 Feb; 2(1):46-52. PubMed ID: 12084295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-based immunotherapy of renal cell carcinoma.
    Thurnher M; Rieser C; Höltl L; Papesh C; Ramoner R; Bartsch G
    Urol Int; 1998; 61(2):67-71. PubMed ID: 10049189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
    Soleimani A; Berntsen A; Svane IM; Pedersen AE
    Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma].
    Wang H; Feng F; Zhu M; Wang R; Wang X; Wu Y; Zhuang Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jan; 31(1):67-71. PubMed ID: 25575061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
    Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
    BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells for the treatment of metastatic renal cell carcinoma: at a low ebb?
    Patard JJ
    Eur Urol; 2006 Jul; 50(1):11-3. PubMed ID: 16713068
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy.
    Mizutani K; Horie K; Kato T; Nakane K; Kawakami K; Fujita Y; Ito M
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1661-1663. PubMed ID: 30515569
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumor vaccines: from gene therapy to dendritic cells--the emerging frontier.
    Vieweg J; Dannull J
    Urol Clin North Am; 2003 Aug; 30(3):633-43, x. PubMed ID: 12953761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma.
    Sievers E; Albers P; Schmidt-Wolf IG; Märten A
    J Urol; 2004 Jan; 171(1):114-9. PubMed ID: 14665857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma.
    Zhan HL; Gao X; Pu XY; Li W; Li ZJ; Zhou XF; Qiu JG
    Chin Med J (Engl); 2012 Nov; 125(21):3771-7. PubMed ID: 23106871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. True immunogenicity of oncofetal antigen/immature laminin receptor protein.
    Coggin JH; Rohrer JW; Barsoum AL
    Cancer Res; 2004 Jul; 64(13):4685; author reply 4685. PubMed ID: 15231682
    [No Abstract]   [Full Text] [Related]  

  • 14. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.
    Höltl L; Rieser C; Papesh C; Ramoner R; Herold M; Klocker H; Radmayr C; Stenzl A; Bartsch G; Thurnher M
    J Urol; 1999 Mar; 161(3):777-82. PubMed ID: 10022683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Specific cellular immunotherapy of renal cell carcinoma. Current status and prospects].
    Ringhoffer M; Gschwend JE
    Urologe A; 2002 May; 41(3):249-57. PubMed ID: 12132274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current immunotherapeutic strategies in renal cell carcinoma.
    Amato RJ
    Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination immunotherapy in renal cell carcinoma.
    Drake CG
    Clin Adv Hematol Oncol; 2016 Feb; 14(2):99-100. PubMed ID: 27057808
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunochemotherapy-associated protein patterns in tumour tissue and serum of patients with metastatic renal cell carcinoma.
    Walter M; Heinze C; Steiner T; Pilchowski R; von Eggeling F; Wunderlich H; Junker K
    Arch Physiol Biochem; 2010; 116(4-5):197-207. PubMed ID: 20836751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5T4 as a target for immunotherapy in renal cell carcinoma.
    Elkord E; Shablak A; Stern PL; Hawkins RE
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1705-9. PubMed ID: 19954280
    [No Abstract]   [Full Text] [Related]  

  • 20. IL-2 immunotherapy-induced increase in IL-12 blood concentrations may depend on an increase in circulating dendritic cell number.
    Lissoni P; Bucovec R; Meregalli S; Fumagalli L; Vigorè L; Ferrante R; Brivio F
    Int J Biol Markers; 1999; 14(3):195-7. PubMed ID: 10569145
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.